Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54

Author: Benzinga Newsdesk | August 12, 2024 10:04am
Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price target from $45 to $54.

Posted In: RNA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist